

Update for PDVAC

# Gavi 6.0

11 October 2025

[gavi.org](https://gavi.org)



# The Gavi 6.0 strategy 'one pager' (short version)

## VISION

Leaving no one behind with immunisation



## MISSION

To **save lives** and **protect people's health** by increasing **equitable and sustainable use of vaccines**

## PRINCIPLES

- Country-led, sustainable
- Community-owned, inclusive
- Zero-dose and missed communities, first priority
- Gender-focused
- Differentiated, fragile-responsive
- Integrated
- Adaptive, resilient
- Climate-sensitive
- Innovative
- Collaborative, accountable

## STRATEGIC GOALS

**1** INTRODUCE AND SCALE UP VACCINES

**2** STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION

**3** IMPROVE PROGRAMMATIC AND FINANCIAL SUSTAINABILITY OF IMMUNISATION PROGRAMMES

**4** ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS

## ENABLERS

- Long-term predictable funding
- One Alliance
- Global political commitment
- Simple, efficient and agile Gavi operating model
- Digitalisation, improved data and evidence
- Collaboration with private sector and development finance institutions

# Gavi Leap | Radical programme designed to deliver Gavi 6.0 in an evolving Global Health ecosystem

## Four principles ...



**Country centricity:** give countries more agency, putting country and community needs at the heart



**Country sovereignty:** fully transition out of donor support



**Limited mandates:** agencies operating in line with their comparative advantages



**Finite lifespans:** agencies define a date to put themselves out of business




## ... and three objectives

**Gavi's internal reforms:** streamlining operational procedures and funding placing countries at the centre

**Merger at the last mile:** greater alignment with close partners, especially at country level, in line with Lusaka Agenda


**The Global Health Leap:** catalyse change around reform of global health architecture



# Zero-dose agenda: ZDC<sup>1</sup> decreased by 5% in 2024 – meeting 2025 target will require >30% reduction

## Number of zero-dose children across Gavi-57 countries

millions



<sup>4</sup>

1. # of Zero Dose Children

# HPV revitalization: The target to reach 86 million girls by the end of Gavi 5.1 is achievable

		Cumulative to 2024	Cumulative to H1 2025	Status	Target (2025)
<b>Impact</b>	Cervical cancer deaths averted (from 2014)	>1.2m	*	●	1.4m
<b>Outcomes</b>	New HPV launches (in Gavi 5.0)	18 Routine 15 MAC	20 Routine 18 MAC	●	27 Routine 28 MAC
	HPVC coverage in Gavi57	56%	*	●	21% (+17pp <sup>1</sup> )
	Girls fully immunized (from 2014)	59.8m	*	●	86m
<b>Other KPIs</b>	Single dose adoption (# countries)	50 approved 1-dose 31 implemented (from approved)			

1. Relative to 2019 coverage baseline.

● On track   ● Moderate delays / challenges   ● Significant delays / challenges   ● No update

Supply outlook has improved; Strong pipeline of planned introductions (10) and campaigns (12) by end of 2025

# Malaria: Malaria vaccine programme on track to meet 2025 targets; countries steadily scaling programmes

		Cumulative to 18th Sep		
<b>Outcomes</b>	Number of Malaria vaccine introductions, scale up	23	6	●
<b>Output</b>	Countries approved for initial intro, scale up	26	15	●
	Countries with VIGs disbursed for initial intro, scale up	24 <sup>1</sup>	6	●
	Number of countries with TA deployed	Ph1: 21 <sup>1</sup>	Ph2: 23	●
	Number of countries that received first shipment	24		●

## Key themes

- Countries adopting **integrated service delivery strategies** as seen in Ethiopia, Nigeria, Burkina Faso and others.
- Alliance focus increasingly on **coverage improvements**
- **Active learning agenda** with ongoing research in 7 countries
- **Gavi collaborating with Global Fund** to optimise suite of malaria interventions in countries

● On track ● Moderate delays / challenges ● Significant delays / challenges ● No update

Rapid pace of vaccine introduction and scale up sustained in 2025 with 25 total introductions expected by end of year

<sup>6</sup> Gavi update to SAGE - September 2025

1: VIGs and TA for vaccine implementation for 3 countries (Kenya, Ghana and Malawi) received as part of MVIP programme  
 2: Currently defined on Total Doses on Gavi Decision Letters up to 2025 for initial introductions  
 NOTE: Ph1 TA is for application support; Ph2 TA is for vaccine implementation support



# Gavi's COVID-19 programme will sunset on 31 Dec 2025

Gavi helped provide 2 billion doses of COVID-19 vaccines to 146 countries through COVAX

This effort showed reduction in disease and unprecedented coordination among multiple stakeholders and resources

In 2024 and 2025 (post-COVAX):

## SCOPE

SAGE March 2024: **single dose annual**, focused on **high-risk groups**.

## DELIVERY

- **30m doses shipped** to 52 countries. **8m more** to be delivered by Dec 2025
- 85% of doses delivered to Gavi 54 countries and 15% to AMC37

Any COVID-19 PHEIC or grade 2/3 emergency will be managed through Gavi's pandemic preparedness, response mechanisms, including First Response Fund

# RSV Maternal Vaccine Programme & Mpox Stockpile for Emergency Response Fully Approved by Gavi Board

## Illustrative timeline ahead:



### KEY MILESTONES:

- MDV Prequalification expected in 2026
- Earliest programme availability in 2027
- ICG Governance Oversight Committee decision
- Program & global stockpile launch – H2 2026

**Note:** PQ dates based on earliest expected dates based on expert input. Timings are based on past experience and may vary across programmes and countries. PQ = WHO pre-qualification. SDV = single-dose vial. MDV = multi-dose vial

# Gavi committed to preparing for a novel tuberculosis vaccine

- VIS 2024 Board in-principle approval an important signal to the global TB vaccine ecosystem
- Gavi co-leads the **Finance & Access Working Group** of the TB Vaccine Accelerator Council
  - In 2025, technical analyses to identify barriers, bottlenecks for financing and access
  - Informed by in-depth consultations and lessons from past mechanisms
- Gavi has also developed the **first global demand and supply forecast** for novel TB vaccines



# Gavi is ready to evaluate next generation vaccines, including novel antigen combinations


Welcome the development of next generation and combination vaccines to address complexities in EPI schedules:

- In July 2025, Gavi Board approved **revised governance pathways** for evaluating novel antigen combinations
- Secretariat will continue supporting the WHO Combination Technical Advisory Group




# The Board met in July to recalibrate the Gavi 6.0 strategy post replenishment

## Board-approved Gavi 6.0 strategy one pager




- Post June replenishment summit, the **Board reassessed Gavi 6.0 priorities** given a ~\$3 billion funding gap
- The Board **identified reductions totaling \$3 billion** – while retaining **the integrity of Gavi 6.0’s ambitious strategy**
- Donors affirmed **commitment to raising full replenishment amount**

# Gavi 6.0 strategy: Recalibration by Strategic Goal



# Gavi 6.0 in line with the planned 5.0 levels, reduced from the recalibration baseline

Percentage % (total cost in US\$ billion)



13 Note: Total might not add up due to rounding

- Vaccine procurement cost
- Fragile & Humanitarian approach
- Partners
- Consolidated cash envelope
- Catalytic Phase (MICs)
- Secretariat Opex

# Board provided in-principle steer on ‘vaccine envelopes’ in Gavi 6.0



Currently, countries apply to Gavi for vaccine support when the need arises – there are no budgetary ceilings for countries on vaccine support

## Objectives of vaccine envelopes



Enhance **financial discipline** in a resource constrained environment



Strengthen **predictable planning, prioritisation, and optimisation** of vaccine programmes



Eprovides agency for **country decision-making** on trade-offs

## How they will be implemented



Envelopes are country-specific **budgets** allocated for 6.0 Gavi vaccine support



Communicated at start of a strategic cycle; countries to then **share with Gavi a five-year plan** for the allocation (‘single application’)



Countries **allocate vaccine funding**, within guardrails, per national/6.0 priorities while retaining the Gavi model (e.g., pooled procurement through UNICEF SD, co-financing)

# Looking towards Gavi 6.0

In a global financially constrained context Gavi countries will:

- require aligned and coordinated support to optimise vaccine portfolios and prioritise immunisation programmes
- Could face potential limitations to fully implement SAGE recommendations



# Thank you